Precision Optics Reports First Quarter Fiscal Year 2025 Financial Results
14 November 2024 - 10:30PM
Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading
designer and manufacturer of advanced optical instruments for the
medical and defense/aerospace industries, announced operating
results on an unaudited basis for its first quarter fiscal year
2025 for the period ended September 30, 2024.
Q1 2025 Financial Highlights (3 Months Ended September
30, 2024):
- Revenue was $4.2 million compared to $4.3 million in the same
quarter of the previous fiscal year and in line with the
expectations provided in September 2024.
- Engineering revenue was $1.9 million compared to $1.9 million
in the same quarter of the previous fiscal year.
- Production revenue was $2.3 million compared to $2.4 million in
the same quarter of the previous fiscal year.
- Gross margins were 26.6% compared to 33.9% in the same quarter
of the previous year.
- Net loss for the quarter was ($1.3) million, compared to $(0.5)
million in the same quarter of the previous year.
- Adjusted EBITDA was $(1.0) million for the quarter compared to
$(0.2) million in the same quarter of the previous
year.
Recent Additional Highlights:
- In October 2024, following FDA 510(k) clearance by its customer
for a single-use urological endoscope imaging assembly, POC
accelerated the timeline for production deliveries against a $9
million order announced in May 2024. POC currently estimates
approximately $3.6 million in product deliveries during its fiscal
year ended June 2025.
- Today, POC announced receipt of an initial $340,000 production
order from a large, global medical device company to provide
initial stocking quantities of a new single-use ophthalmic
endoscope. POC expects follow-on orders to support first year
requirements after launch with delivery rates two to three times
those of the initial stocking order.
Precision Optics' CEO, Joseph Forkey, commented, “The first
quarter results that we released today were in line with the
expectations we provided in September 2024. We are seeing a rapid
ramp in production revenue commencing in the current quarter with
expectations for substantial revenue growth and dramatic
improvements in adjusted EBITDA for the second quarter ending
December 31, 2024 and further improvements throughout this fiscal
year.”
“Anticipated sequential revenue growth will be driven by a
number of product development programs transitioning into
production or ramping from recent production levels. We continue to
see acceleration of single-use applications. We now have two
programs beginning production this year and additional single-use
programs in our product development pipeline.”
“We are at an inflection point leading to a high growth
production business, building off of the investments we’ve made
over many years to advance our single-use product solutions. This
is an exciting time for Precision Optics,” Dr. Forkey
concluded.
The following table summarizes the first quarter
(unaudited) results for the periods ended September 30, 2024, and
2023:
|
|
Three Months |
|
|
Ended September 30 |
|
|
|
2024 |
|
|
2023 |
|
Revenues |
$ |
4,197,053 |
|
$ |
4,321,255 |
|
|
|
|
|
Gross
Profit |
|
1,117,330 |
|
|
1,463,611 |
|
|
|
|
|
Stock
Compensation Expenses |
|
149,364 |
|
|
108,746 |
|
Other |
|
2,214,907 |
|
|
1,760,158 |
|
Total Operating
Expenses |
|
2,364,271 |
|
|
1,868,904 |
|
|
|
|
|
Operating
Income (Loss) |
|
(1,246,941 |
) |
|
(405,293 |
) |
|
|
|
|
Net Income
(Loss) |
|
(1,311,247 |
) |
|
(464,415 |
) |
|
|
|
|
Income (Loss)
per Share |
|
|
|
Basic
& Fully Diluted |
$ |
(0.21 |
) |
$ |
(0.08 |
) |
|
|
|
|
|
|
|
Weighted
Average Common Shares Outstanding |
|
Basic
& Fully Diluted |
|
6,216,630 |
|
|
6,066,518 |
|
Conference Call DetailsDate and
Time: Thursday, November 14, at 5:00pm ET
Call-in Information: Interested parties can access the
conference call by dialing (844) 735-3662 or (412) 317-5705.
Live Webcast Information: Interested parties can access the
conference call via a live webcast, which is available at
https://app.webinar.net/rOVEypeYAoR.
Replay: A teleconference replay of the call will be available
until November 21, 2024, at (877) 344-7529 or (412) 317-0088,
replay access code 7879688. A webcast replay will be available at
https://app.webinar.net/rOVEypeYAoR.
About Precision Optics
CorporationFounded in 1982, Precision Optics is a
vertically integrated optics company primarily focused on
leveraging its proprietary micro-optics and 3D imaging technologies
to the healthcare and defense/aerospace industries by providing
services ranging from new product concept through mass manufacture.
Utilizing its leading-edge in-house design, prototype, regulatory
and fabrication capabilities as well as its Lighthouse Imaging
division's electronic imaging expertise and its Ross Optical
division's high volume world-wide sourcing, inspecting and
production resources, the Company designs and manufactures
next-generation product solutions for the most challenging customer
requirements. Within healthcare, Precision Optics enables next
generation medical device companies around the world to meet the
increasing demands of the surgical community who require more
enhanced and smaller imaging systems for minimally invasive
surgery, including single-use medical devices, as well as 3D
endoscopy systems to support the rapid proliferation of surgical
robotic systems. In addition to these next generation applications,
Precision Optics has supplied top tier medical device companies
with a wide variety of optical products for decades, including
complex endocouplers and specialized endoscopes. The Company is
also leveraging its technical proficiency in micro-optics to enable
leading edge defense/aerospace applications which require the
highest quality standards and the optimization of size, weight and
power. For more information, please visit www.poci.com.
Non-GAAP Financial Measures
Precision Optics has provided in this press
release financial information that has not been prepared in
accordance with accounting principles generally accepted in the
Unites States of America (“non-GAAP”). The non-GAAP financial
measure is Adjusted EBITDA (earnings before interest, taxes,
depreciation and amortization). Adjusted EBITDA also excludes from
Net Income (Loss) the effect of stock-based compensation AND
DEPRECIATION, AMORTIZATION AND INTEREST EXPENSE.
This non-GAAP financial measure assists
Precision Optics management in comparing its operating performance
over time because certain items may obscure the underlying business
trends and make comparisons of long-term performance difficult, as
they are of a nature and/or size that occur with inconsistent
frequency or relate to discrete acquisition or restructuring plans
that are fundamentally different from the ongoing productivity of
the Company. Precision Optics management also believes that
presenting this measure allows investors to view its performance
using the same measures that the Company uses in evaluating its
financial and business performance and trends.
Non-GAAP financial measures should not be
considered in isolation from, or as a substitute for, financial
information calculated in accordance with GAAP. Investors are
encouraged to review the reconciliation of non-GAAP measures to
their most directly comparable GAAP financial measures. A
reconciliation of the non-GAAP financial measure presented above to
GAAP results has been provided in the financial tables included
with this press release.
About Forward-Looking
StatementsThis press release contains forward-looking
statements. Forward-looking statements include, but are not limited
to, statements that express the Company's intentions, beliefs,
expectations, strategies, predictions or any other statements
related to the Company's future activities or future events or
conditions. Forward-looking statements in this press release
include, without limitation, future levels of expected product
deliveries and projections related to future EBITDA goals. These
statements are based on current expectations, estimates and
projections about the Company's business based, in part, on
assumptions made by the Company's management. These statements are
not guarantees of future performance and involve risks,
uncertainties and assumptions that are difficult to predict.
Therefore, actual outcomes and results may differ materially from
what is expressed or forecasted in the forward-looking statements
due to numerous risk factors, including those risks discussed in
the Company's annual report on Form 10-K and in other documents
that we file from time to time with the SEC. Any forward-looking
statements speak only as of the date on which they are made, and
the Company does not undertake any obligation to update any
forward-looking statement, except as required by law.
Company Contact: PRECISION
OPTICS CORPORATION22 East BroadwayGardner, Massachusetts
01440-3338Telephone: 978-630-1800
Investor Contact:LYTHAM
PARTNERS, LLCRobert BlumTelephone:
602-889-9700poci@lythampartners.com
|
|
PRECISION OPTICS CORPORATION, INC.
CONSOLIDATED BALANCE
SHEETS(UNAUDITED) |
|
|
|
|
|
September 30, |
|
|
June 30, |
|
|
|
2024 |
|
|
2024 |
|
ASSETS |
|
|
|
|
|
|
|
|
Current Assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
635,572 |
|
|
$ |
405,278 |
|
Accounts receivable, net of allowance for doubtful accounts of
$103,224 at September 30, 2024 and $118,872 at June 30, 2024 |
|
|
3,123,595 |
|
|
|
3,545,491 |
|
Inventories |
|
|
3,460,621 |
|
|
|
2,868,100 |
|
Prepaid expenses |
|
|
288,475 |
|
|
|
299,364 |
|
Total current assets |
|
|
7,508,263 |
|
|
|
7,118,233 |
|
|
|
|
|
|
|
|
|
|
Fixed Assets: |
|
|
|
|
|
|
|
|
Machinery and equipment |
|
|
3,346,694 |
|
|
|
3,341,194 |
|
Leasehold improvements |
|
|
819,954 |
|
|
|
810,914 |
|
Furniture and fixtures |
|
|
426,234 |
|
|
|
416,425 |
|
|
|
|
4,592,882 |
|
|
|
4,568,533 |
|
Less—accumulated depreciation
and amortization |
|
|
4,123,250 |
|
|
|
4,074,960 |
|
Net fixed assets |
|
|
469,632 |
|
|
|
493,573 |
|
|
|
|
|
|
|
|
|
|
Operating lease right-to-use
asset |
|
|
146,247 |
|
|
|
189,999 |
|
Patents, net |
|
|
290,309 |
|
|
|
286,559 |
|
Goodwill |
|
|
8,824,210 |
|
|
|
8,824,210 |
|
Total other assets |
|
|
9,260,766 |
|
|
|
9,300,768 |
|
TOTAL ASSETS |
|
$ |
17,238,661 |
|
|
$ |
16,912,574 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND
STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
Current Liabilities: |
|
|
|
|
|
|
|
|
Revolving line of credit |
|
$ |
500,000 |
|
|
$ |
1,000,000 |
|
Current portion of capital lease obligation |
|
|
38,886 |
|
|
|
41,113 |
|
Current maturities of long-term debt |
|
|
285,901 |
|
|
|
276,928 |
|
Accounts payable |
|
|
2,143,351 |
|
|
|
1,397,313 |
|
Contract liabilities |
|
|
1,106,546 |
|
|
|
1,172,350 |
|
Accrued compensation and other |
|
|
1,115,135 |
|
|
|
840,662 |
|
Operating lease liability |
|
|
146,247 |
|
|
|
178,450 |
|
Total current liabilities |
|
|
5,336,066 |
|
|
|
4,906,816 |
|
|
|
|
|
|
|
|
|
|
Capital lease obligation, net
of current portion |
|
|
18,384 |
|
|
|
27,369 |
|
Long-term debt, net of current
maturities and debt issuance costs |
|
|
1,746,764 |
|
|
|
1,899,052 |
|
Operating lease liability, net
of current portion |
|
|
- |
|
|
|
11,549 |
|
Total liabilities |
|
|
7,101,214 |
|
|
|
6,844,786 |
|
|
|
|
|
|
|
|
|
|
Stockholders’ Equity: |
|
|
|
|
|
|
|
|
Common stock, $0.01 par value: 50,000,000 shares authorized; issued
and outstanding – 6,350,170 shares at September 30, 2024 and
6,073,939 at June 30, 2024 |
|
|
63,502 |
|
|
|
60,739 |
|
Additional paid-in capital |
|
|
62,575,576 |
|
|
|
61,197,433 |
|
Accumulated deficit |
|
|
(52,501,631 |
) |
|
|
(51,190,384 |
) |
Total stockholders’ equity |
|
|
10,137,447 |
|
|
|
10,067,788 |
|
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES AND
STOCKHOLDERS’ EQUITY |
|
$ |
17,238,661 |
|
|
$ |
16,912,574 |
|
|
|
PRECISION OPTICS
CORPORATION, INC.CONSOLIDATED STATEMENTS OF
OPERATIONSFOR THE THREE MONTHS
ENDEDSEPTEMBER 30, 2024 AND
2023(UNAUDITED) |
|
|
|
|
|
Three MonthsEnded September
30, |
|
|
|
2024 |
|
|
2023 |
|
Revenues |
|
$ |
4,197,053 |
|
|
$ |
4,321,255 |
|
|
|
|
|
|
|
|
|
|
Cost of Goods Sold |
|
|
3,079,723 |
|
|
|
2,857,644 |
|
Gross Profit |
|
|
1,117,330 |
|
|
|
1,463,611 |
|
|
|
|
|
|
|
|
|
|
Research and Development
Expenses |
|
|
400,659 |
|
|
|
212,758 |
|
Selling, General and
Administrative Expenses |
|
|
1,963,612 |
|
|
|
1,656,146 |
|
Total Operating Expenses |
|
|
2,364,271 |
|
|
|
1,868,904 |
|
|
|
|
|
|
|
|
|
|
Operating Loss |
|
|
(1,246,941 |
) |
|
|
(405,293 |
) |
|
|
|
|
|
|
|
|
|
Interest Expense |
|
|
(64,306 |
) |
|
|
(59,122 |
) |
|
|
|
|
|
|
|
|
|
Net Loss |
|
$ |
(1,311,247 |
) |
|
$ |
(464,415 |
) |
|
|
|
|
|
|
|
|
|
Loss Per Share: |
|
|
|
|
|
|
|
|
Basic & Fully Diluted |
|
$ |
(0.21 |
) |
|
$ |
(0.08 |
) |
|
|
|
|
|
|
|
|
|
Weighted Average Common Shares
Outstanding: |
|
|
|
|
|
|
|
|
Basic & Fully Diluted |
|
|
6,216,630 |
|
|
|
6,066,518 |
|
|
|
PRECISION OPTICS CORPORATION, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’
EQUITYFOR THE THREE MONTHS
ENDEDSEPTEMBER 30, 2024 AND
2023(UNAUDITED) |
|
|
|
|
|
Three Month Period Ended September 30, 2024 |
|
|
|
Number of Shares |
|
|
CommonStock |
|
AdditionalPaid-inCapital |
|
|
AccumulatedDeficit |
|
|
TotalStockholders’Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, July 1, 2024 |
|
|
6,073,939 |
|
|
$ |
60,739 |
|
|
$ |
61,197,433 |
|
|
$ |
(51,190,384 |
) |
|
$ |
10,067,788 |
|
Issuance of common stock in
registered direct offering |
|
|
265,868 |
|
|
|
2,659 |
|
|
|
1,201,883 |
|
|
|
|
|
|
|
1,204,542 |
|
Proceeds from exercise of
stock option |
|
|
10,363 |
|
|
|
104 |
|
|
|
26,896 |
|
|
|
|
|
|
|
27,000 |
|
Stock-based compensation |
|
|
– |
|
|
|
– |
|
|
|
149,364 |
|
|
|
– |
|
|
|
149,364 |
|
Net loss |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(1,311,247 |
) |
|
|
(1,311,247 |
) |
Balance, September 30,
2024 |
|
|
6,350,170 |
|
|
$ |
63,502 |
|
|
$ |
62,575,576 |
|
|
$ |
(52,501,631 |
) |
|
$ |
10,137,447 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Month Period Ended September 30, 2023 |
|
|
|
Number of Shares |
|
|
CommonStock |
|
|
AdditionalPaid-inCapital |
|
|
AccumulatedDeficit |
|
|
TotalStockholders’Equity |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, July 1, 2023 |
|
|
6,066,518 |
|
|
$ |
60,665 |
|
|
$ |
60,224,934 |
|
|
$ |
(48,239,007 |
) |
|
$ |
12,046,592 |
|
Stock-based compensation |
|
|
– |
|
|
|
– |
|
|
|
108,746 |
|
|
|
|
|
|
|
108,746 |
|
Net loss |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
(464,415 |
) |
|
|
(464,415 |
) |
Balance, September 30,
2023 |
|
|
6,066,518 |
|
|
$ |
60,665 |
|
|
$ |
60,333,680 |
|
|
$ |
(48,703,422 |
) |
|
$ |
11,690,923 |
|
|
PRECISION OPTICS CORPORATION, INC. AND
SUBSIDIARIES |
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL
MEASURES |
ADJUSTED EBITDA |
|
|
|
Three Months |
September 30, |
|
|
2024 |
|
|
|
2023 |
|
Net Income (loss) (GAAP) |
|
$ |
(1,311,247 |
) |
|
|
$ |
(464,415 |
) |
|
|
|
|
|
|
|
|
Stock
based compensation |
|
|
149,364 |
|
|
|
|
108,746 |
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
48,290 |
|
|
|
|
51,564 |
|
|
|
|
|
|
|
|
|
State
Income Taxes |
|
|
- |
|
|
|
|
- |
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
64,306 |
|
|
|
|
59,122 |
|
|
|
|
|
|
|
|
|
Adjusted EBITDA (non-GAAP) |
|
$ |
(1,049,287 |
) |
|
|
$ |
(244,983 |
) |
|
|
|
|
|
|
|
|
Precision Optics (NASDAQ:POCI)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Precision Optics (NASDAQ:POCI)
Historical Stock Chart
Von Jan 2024 bis Jan 2025